Live·Verified funding discovery · 2026.2
874 grants · 19 open · 435 companies · 2640 concepts874 / 19 / 435 / 2640
COMPANIESCompanies rated · 435 (no change)PROJECTSProjects rated · 70 (no change)CATALOGUE874 grants in catalogue · 19 open right nowPOWERED BYOpen Longevity · 501(c)(3) · Sherman Oaks, CACOMPANIESCompanies rated · 435 (no change)PROJECTSProjects rated · 70 (no change)CATALOGUE874 grants in catalogue · 19 open right nowPOWERED BYOpen Longevity · 501(c)(3) · Sherman Oaks, CA
← Back to Eternal Search

David Hallal

individual
Capital ownerEcosystem influencer

About

David Hallal is a biotech executive best known for leading Alexion, co-founding ElevateBio, and serving as chairman and CEO or executive chairman across several cell and gene therapy companies. As of April 27, 2025, he is Chief Executive Officer and Chairman of Scholar Rock. He also serves as Executive Chairman of ElevateBio and AlloVir, chairs iTeos Therapeutics, and sits on the board of Seer Biosciences.

Areas of interest

biotechrare diseasecell therapygene therapygenetic medicinesdrug developmentbiomanufacturingoncology